Skip to content


  • Poster presentation
  • Open Access

Pilot and feasibility studies: what's the point?

  • 1,
  • 2,
  • 2 and
  • 2
Trials201516 (Suppl 2) :P22

  • Published:


  • Public Health
  • Clinical Trial
  • Research Design
  • Feasibility Study
  • Trial Design


The appropriateness of research design and methodology of clinical trials is paramount if we are to succeed in reducing the amount of waste in research. Pilot and feasibility studies serve an important role in determining the most appropriate design and whether the trial will succeed to completion.

Aims and Objectives

The study will assess the role of pilot and feasibility studies in the design of clinical trials funded by the Health Technology Assessment (HTA) programme.


There are three phases to the study: 1. Literature review, 2. Review of the ongoing HTA trial portfolio and, 3. Review of the HTA portfolio of published trials to determine the added value of the inclusion of a pilot or feasibility study. A list of HTA trials will be retrieved from three cohorts: completed standalone pilot or feasibility studies; completed and ongoing clinical trials which include an internal pilot or feasibility study; and successful applications in pre-contracting status in the HTA programme.


The results of the study will still be in development. The number of included trials and proposed checklist/classification system will be presented to determine how pilot and feasibility studies are used to inform the trial design and whether those that include a pilot or feasibility study recruit patients on time and within target.


The findings from this study will be important in the context of the adding value in research agenda. This is partly due to the lack of existing evidence on the role of pilot and feasibility studies.

Authors’ Affiliations

University of Southampton, Southampton, UK
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Southampton, UK


© Pek et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.